ATE492563T1 - Vollständige humane monoklonale antikörper gegen il-13 - Google Patents

Vollständige humane monoklonale antikörper gegen il-13

Info

Publication number
ATE492563T1
ATE492563T1 AT05823172T AT05823172T ATE492563T1 AT E492563 T1 ATE492563 T1 AT E492563T1 AT 05823172 T AT05823172 T AT 05823172T AT 05823172 T AT05823172 T AT 05823172T AT E492563 T1 ATE492563 T1 AT E492563T1
Authority
AT
Austria
Prior art keywords
human monoclonal
monoclonal antibodies
antibodies against
antibodies
complete human
Prior art date
Application number
AT05823172T
Other languages
English (en)
Inventor
Ian Foltz
Raffaella Faggioni
Giorgio Senaldi
Kathy Manchulenko
Jaspal S Kang
Palaniswami Rathanaswami
Kiran Ahluwalia
Orit Foord
Scott Klakamp
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE492563T1 publication Critical patent/ATE492563T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05823172T 2004-11-17 2005-11-15 Vollständige humane monoklonale antikörper gegen il-13 ATE492563T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62913504P 2004-11-17 2004-11-17
US72860405P 2005-10-19 2005-10-19
PCT/US2005/041536 WO2006055638A2 (en) 2004-11-17 2005-11-15 Fully human monoclonal antibodies to il-13

Publications (1)

Publication Number Publication Date
ATE492563T1 true ATE492563T1 (de) 2011-01-15

Family

ID=36407728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823172T ATE492563T1 (de) 2004-11-17 2005-11-15 Vollständige humane monoklonale antikörper gegen il-13

Country Status (10)

Country Link
US (2) US7585500B2 (de)
EP (1) EP1824886B1 (de)
JP (1) JP2008520684A (de)
AT (1) ATE492563T1 (de)
AU (1) AU2005307831A1 (de)
CA (1) CA2587903A1 (de)
DE (1) DE602005025525D1 (de)
MX (1) MX2007005866A (de)
TW (1) TW200621802A (de)
WO (1) WO2006055638A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444989A1 (de) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2007036745A2 (en) * 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
MY144906A (en) * 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
WO2008003514A2 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2041570A4 (de) * 2006-07-12 2010-02-24 Trellis Bioscience Inc CellSpotTM-ANWENDUNGEN
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
KR101544108B1 (ko) * 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
AU2009283008A1 (en) 2008-08-20 2010-02-25 Centocor Ortho Biotech Inc. Engineered anti-IL-13 antibodies, compositions, methods and uses
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2010108154A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
CN103339145A (zh) 2010-09-22 2013-10-02 安姆根有限公司 运载体免疫球蛋白及其用途
CA2814431A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
JP6005657B2 (ja) 2010-12-16 2016-10-12 ジェネンテック， インコーポレイテッド Ｔｈ２阻害に関連する診断及び治療
WO2013016613A1 (en) * 2011-07-28 2013-01-31 Janssen Biotech, Inc. Pentraxin 3 association with asthma
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US9758578B2 (en) 2013-12-26 2017-09-12 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody
CA2936877C (en) * 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
WO2015155710A1 (en) 2014-04-11 2015-10-15 Novartis Ag Methods of selectively treating asthma using il-13 antagonists
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
MA40164A (fr) * 2014-06-27 2017-05-03 Sanofi Sa Anticorps bispécifiques anti-il4-il13
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
JP6501650B2 (ja) * 2015-06-25 2019-04-17 田辺三菱製薬株式会社 ヒト抗ｉｌ−３３中和モノクローナル抗体
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
JP2019527535A (ja) * 2016-05-18 2019-10-03 上海開拓者生物医薬有限公司Ｓｈａｎｇｈａｉ Ｐｈａｒｍａｅｘｐｌｏｒｅｒ Ｃｏ．， Ｌｔｄ． Ｉｌ−１３抗体およびその製造方法と使用
US11046764B2 (en) 2017-01-03 2021-06-29 Trellis Bioscience, Llc Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CN115920032A (zh) 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
US12221484B2 (en) 2019-03-29 2025-02-11 Lankenau Institute For Medical Research Anti-NMDA receptor antibodies and methods of use
AU2020323901A1 (en) * 2019-07-26 2022-02-24 Amgen Inc. Anti-IL13 antigen binding proteins
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
CN113248625B (zh) * 2021-04-12 2022-04-05 安徽医科大学第一附属医院 融合蛋白、编码融合蛋白的基因、重组载体及它们的应用
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024151996A1 (en) * 2023-01-12 2024-07-18 National Jewish Health Intelectin-1 (itln-1) inhibitors for use in treating mucus obstruction in severe asthma
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
JPS58166633A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
JPS58166634A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62170639A (ja) 1986-01-22 1987-07-27 株式会社システムメンテナンス 防蟻板の取付け工法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH0368180A (ja) 1989-08-07 1991-03-25 Nippon Telegr & Teleph Corp <Ntt> 超伝導接合素子
JP2863205B2 (ja) 1989-08-30 1999-03-03 カルソニック株式会社 扁平形状を有する樹脂成形品の製造方法及びその装置、並びにフラットモータのコンミュテータ
JPH0651303B2 (ja) 1989-08-30 1994-07-06 株式会社クボタ 繊維強化樹脂発泡薄板の製造方法
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
EP0940468A1 (de) 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3086506B2 (ja) 1991-09-27 2000-09-11 三洋電機株式会社 電気掃除機
JP3086507B2 (ja) 1991-10-02 2000-09-11 旭化成工業株式会社 熱可塑性合成樹脂成形品
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
EP0633929B1 (de) 1992-04-01 2004-03-03 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
JPH07508179A (ja) * 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2121096A1 (en) 1993-04-22 1994-10-23 Weng Tao Monoclonal antibodies to bovine cytokines
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CA2196200A1 (en) 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US20010053371A1 (en) 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5830453A (en) 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
EP0773288A3 (de) 1995-08-29 1997-07-09 Kirin Brewery Chimäre-Tier und dessen Verfahren zur Herstellung
EP0907730B1 (de) 1995-10-23 2009-10-07 Zenyth Operations Pty Ltd Hemopoietin-rezeptor und dafür kodierende genetische sequenzen
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6511848B2 (en) 1996-04-17 2003-01-28 Winfried Albert Process for producing and multiplying lymphocytes
US5910417A (en) 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (de) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
WO1998031384A1 (en) 1997-01-22 1998-07-23 The Wistar Institute Of Anatomy & Biology Methods and compositions using interleukin-13 for enhancing immune responses
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6824986B1 (en) 1997-10-06 2004-11-30 University Of Cincinnati Methods for measuring in vivo cytokine production
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20030129132A1 (en) 1998-02-17 2003-07-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services IL-13 receptor specific chimeric proteins & uses thereof
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
AU2750800A (en) * 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
CA2362264C (en) 1999-02-08 2012-05-08 Medvet Science Pty. Ltd. Cytokine-binding domain
IL140054A0 (en) 1999-04-06 2002-02-10 Univ East Carolina Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU783250B2 (en) 1999-06-17 2005-10-06 Dartmouth College Autologous adoptive immunotherapy with primed antigen-specific T cells or B cells
EP1206288B1 (de) 1999-08-02 2007-01-10 The Regents Of The University Of Michigan Zielgerichtete fiberlose radiative effektoren
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
US6645486B1 (en) 2000-01-25 2003-11-11 Ludwig Institute For Cancer Research Method of treatment with IL-9 conjugate
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
WO2001067103A1 (en) 2000-03-06 2001-09-13 Bioseek, Inc. Function homology screening
CA2406245A1 (en) 2000-04-18 2001-10-25 Schering Corporation Il-174 uses, compositions and methods
AU2001274934A1 (en) 2000-05-24 2001-12-03 Nexell Therapeutics Inc. Human circulating dendritic cell compositions and methods
GB0019638D0 (en) 2000-08-09 2000-09-27 European Molecular Biology Lab Embl Peptide mimetics
DK1333850T3 (da) 2000-10-20 2008-12-01 Genetics Inst Anvendelse af IL-13-inhibitorer til behandling af tumorer
EP1327681A4 (de) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degradierte Agonisten Antikörper
US20050065319A1 (en) 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
AU2002305236A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
US6599914B2 (en) 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
CA2450147A1 (en) 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof
ATE540695T1 (de) 2001-06-08 2012-01-15 Genaera Corp Verfahren zur modulation von il-13
AU2002334969A1 (en) 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
CA2461665A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040234499A1 (en) * 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
EP1578912A4 (de) 2001-10-26 2007-12-26 Centocor Inc Il-13-mutein-proteine, antikörper, zusammensetzungen, verfahren und verwendungen
ATE374944T1 (de) 2001-12-03 2007-10-15 Abgenix Inc Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
US20040241653A1 (en) 2001-12-31 2004-12-02 Elena Feinstein Methods for identifying marker genes for cancer
US20030143658A1 (en) 2002-01-28 2003-07-31 Casella Linda J. Richardson Rapid methods and devices for the detection of coliform and the detection and confirmation of E. coil
CA2482633A1 (en) 2002-02-11 2003-08-21 The Trustees Of The University Of Pennsylvania Oligomeric molecules and uses thereof
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AUPS194902A0 (en) 2002-04-24 2002-06-06 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2003092610A2 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
ES2384439T3 (es) 2002-06-14 2012-07-04 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedimientos de tratamiento y prevención de colitis que se implican IL-13 y células NK-T
EP2363710B1 (de) 2002-08-08 2015-07-01 Baylor College Of Medicine Isolierung und identifizierung von t-zellen
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
AU2003270330B2 (en) 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
EP1444989A1 (de) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
WO2004092404A2 (en) 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
US20040248205A1 (en) 2003-04-16 2004-12-09 Stern Lawrence J. Major histocompatibility complex (MHC)-peptide arrays
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP4860470B2 (ja) 2003-08-06 2012-01-25 ザ プロクター アンド ギャンブル カンパニー 表面処理された吸収性ゲル化材料を製造するための方法
DK2805728T3 (da) * 2003-12-23 2020-04-20 Genentech Inc Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf
EP1720573A4 (de) * 2004-02-27 2008-04-02 Centocor Inc Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit il-13
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질

Also Published As

Publication number Publication date
JP2008520684A (ja) 2008-06-19
TW200621802A (en) 2006-07-01
EP1824886B1 (de) 2010-12-22
US7994302B2 (en) 2011-08-09
HK1111169A1 (en) 2008-08-01
US20100047253A1 (en) 2010-02-25
AU2005307831A1 (en) 2006-05-26
WO2006055638A3 (en) 2006-08-24
WO2006055638A2 (en) 2006-05-26
US7585500B2 (en) 2009-09-08
MX2007005866A (es) 2007-11-12
DE602005025525D1 (de) 2011-02-03
CA2587903A1 (en) 2006-05-26
EP1824886A2 (de) 2007-08-29
US20060140948A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
TW200716182A (en) Antibodies directed to CD20 and uses thereof
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
TW200637873A (en) Antibodies against interleukin-1 beta
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
ATE420660T1 (de) Antikörper gegen parath-hormon (pth) und ihre verwendungen
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2004084823A3 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
MXPA05005925A (es) Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
MX2007001338A (es) Anticuerpos antagonistas de il-17.
TW200801040A (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
WO2006104978A3 (en) Antibodies against the tenascin major antigens
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
EP2548583A3 (de) Verfahren zur behandlung von ovarial- und nierenkarzinom mit antikörpern gegen t-zell-immunglobulin-domänen- und mucin-domänen-1-(tim-1)-antigen
WO2006055704A3 (en) Antibodies directed to ten-m proteins and uses thereof
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties